A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users.
A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users.
复制标题
不同激素替代药物治疗持续率的比较：对新使用者的药房声明进行 9 个月的回顾性纵向分析。
DOI：
10.1097/00042192-200310010-00007
复制
发表时间：
2003
期刊：
影响因子：
2.7
通讯作者：
Kirsten J. Axelsen
中科院分区：
文献类型：
--
作者：
J. Simon;S. Wysocki;J. Brandman;Kirsten J. Axelsen
目的：评估使用六种不同激素替代疗法（HRT）的女性的治疗持续率。设计：回顾性，纵向分析药房索赔数据进行了7,120名妇女谁是六个HRT方案的新用户。在9个月结束时检查治疗的继续率。此外，使用逻辑模型确定每种产品继续使用的比值比，该模型控制了患者年龄和提供者年龄、性别、专业和地理位置的潜在影响。研究结果：与其他HRT方案相比，口服1 mg醋酸炔诺酮/5 μ g炔雌醇（EE）（femhrt，Pfizer Inc，纽约，NY，美国）的患者在9个月结束时的治疗继续率显著更高。与使用0.625 mg结合马雌激素/2.5 mg或5 mg醋酸甲羟孕酮（Prempro，Wyeth，麦迪逊，新泽西州，美国）的患者相比，使用1 mg醋酸炔诺酮/5 μ g EE的患者继续治疗的可能性高52%。在55岁或以上的女性中，在分析期间没有转换HRT的女性，在美国中部和东北部地区接受治疗的女性，以及由产科医生/妇科医生（初级保健医生）或女性（男性）提供者就诊的女性中，继续治疗的比例显着较高。结论：较新的连续联合HRT（如1 mg醋酸炔诺酮/5 μ g EE）的治疗持续率较高，可能导致长期依从性改善，因此更好地保护绝经后妇女免受骨质疏松症的影响。
OBJECTIVE: To estimate the rate of therapy continuation among women using six different hormone replacement therapies (HRTs). DESIGN: A retrospective, longitudinal analysis of pharmacy claims data was conducted for 7,120 women who were new users of six HRT regimens. Continuation rates of therapies were examined at the end of the 9-month period. In addition, the odds ratio of continuation for each product was determined using a logistic model, which controlled for the potential influence of a patient's age and a provider's age, gender, specialty, and geographical location. RESULTS: Treatment continuation rates at the end of the 9-month period were significantly higher among patients prescribed oral 1 mg norethindrone acetate/5 microgram ethinyl estradiol (EE) (femhrt, Pfizer Inc, New York, NY, USA) compared with other HRT regimens. Patients prescribed 1 mg norethindrone acetate/5 microgram EE were 52% more likely to continue therapy compared with patients prescribed 0.625 mg conjugated equine estrogens/2.5 mg or 5 mg medroxyprogesterone acetate (Prempro, Wyeth, Madison, NJ, USA). Significantly higher rates of therapy continuation were seen in women aged 55 years or older, those who did not switch HRT during the analysis, those who received care in the central and northeast regions of the United States, and those who were seen by obstetricians/gynecologists (v primary care physicians) or female (v male) providers. CONCLUSIONS: The higher rates of treatment continuation seen with newer continuous combined HRTs, such as 1 mg norethindrone acetate/5 microgram EE, may lead to improved long-term compliance and, therefore, better protection against osteoporosis in postmenopausal women.
影响因子：
158.5
作者：
Grodstein, F;Stampfer, MJ;Hennekens, CH
通讯作者：
Hennekens, CH